Caribou Biosciences (CRBU) Shares Outstanding (Weighted Average) (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $95.9 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $95.9 million, up 3.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $95.9 million (up 3.43% YoY), and the FY2025 annual result was $93.4 million, up 3.4% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $95.9 million in Q1 2026 per CRBU's latest filing, from $93.4 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $95.9 million in Q1 2026 and troughed at $60.5 million in Q1 2022.
• A 5-year average of $78.6 million and a median of $89.3 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) soared 537.37% in 2022, then grew 1.06% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $60.8 million in 2022, then grew by 21.39% to $73.8 million in 2023, then grew by 22.37% to $90.3 million in 2024, then gained by 3.4% to $93.4 million in 2025, then gained by 2.65% to $95.9 million in 2026.
• Business Quant data shows CRBU's Shares Outstanding (Weighted Average) at $95.9 million in Q1 2026, $93.4 million in Q4 2025, and $93.3 million in Q3 2025.